Graduate Student Directory

---

Bio

---

Curriculum Vitae

---

Education:

• A.S., Chemistry - Alpena Community College, 2016
• A.AS., Industrial Chemistry Technologies - Ferris State University, 2018
• B.S., Industrial Chemistry Technologies - Ferris State University, 2019

---

Research Areas:

In-silico development and synthesis of novel selective Peroxisome Proliferator Activated Receptors (PPAR) agonists, and evaluation of their role in modulating inflammatory disease pathologies, i.e. neurodegeneration and Non-Alcoholic SteatoHepatitis (NASH). Using high throughput virtual screening, ligand docking, and molecular dynamics Steinke was able to identify characteristic molecular behavior that correlated to specific types of PPAR agonists and antagonists for further compound lead optimization.

Lead compounds were further screened and filtered using ADMET predictive software to identify strengths and weaknesses associated with varying chemical moiety’s that would enhance absorption, cell permeability, and decrease toxicity. In addition, he is investigating novel flaving-containing monooxygenase 3 (FMO3) inhibitors and the role in metabolism of the gut-derived metabolite Trimethylamine (TMA) conversion to trimethylamine n-oxide (TMAO).

---

Ian Steinke is originally from Alpena, Michigan where he received an associate’s degree in chemistry from Alpena Community College. From there he transitioned to Big Rapids, Michigan to attend Ferris State University where he received both an associates degree and bachelor of science for industrial chemistry technologies.

At Ferris State University, Steinke became involved in two separate research projects involving organic chemistry and medicinal chemistry. This spurred his interest in pursuing graduate school at Auburn University’s Harrison College of Pharmacy for medicinal chemistry. Currently he am learning how to apply both synthetic and medicinal chemistry concepts to develop novel compounds for disease intervention. In conjunction, he is also learning how to test compounds in vitro to validate activity.

---

Presentations

• “DESIGN AND DEVELOPMENT OF NOVEL DUAL PPAR δ/α AGONIST FOR NEURODEGENERATIVE DISEASE”, Via Research Recognition Day – Auburn Campus. February 18th, 2022
• “Design and development of novel Pan-PPAR agonist for hepatic steatosis”, Boshell 13th Annual Research Day. September 17th, 2021
• “Novel pan PPAR agonist enhances synapse stability and growth in a model of Alzheimer’s Disease.” 21st International Conference on Alzheimer's Drug. October 5-6, 2020
• “Gut microbiota metabolite, TMAO, induces microglial activation and senescence in rodent models with memory impairment.”, Center for Neuroscience Initiative Convention. February 28, 2020
• “An Investigation of the Hydrogen Bond Connectivity between Sulfa Drugs and Hydrogen Bond Acceptors in Cocrystals”, American Chemical Society National Convention. March 18-22, 2018
• “An Investigation of the Hydrogen Bond Connectivity between Sulfa Drugs and Nitrogen Containing Co-formers and Co-crystals”, Ferris State University Student Research Fellowship Presentation. Summer 2017

---

Publications

• Steinke, I., Amin, R.H., “Design of Novel PPAR Agonist for Neurodegenerative Disease.”, Nuclear Receptors, Springer International Publishing
• Govindarajulu, M., Pinky, P.D., Steinke, I., Bloemer, J., Ramesh, S., Kariharan, T., Rella, R.T., Dhanasekaran, M., Suppiramaniam, V., and Amin, R.H., Published August 12th, 2020, “Gut metabolite TMAO induces synaptic plasticity deficits by promoting Endoplasmic Reticulum stress.”, Frontiers in Molecular Neuroscience
• Steinke, I., Ghanei, N., Govindarajulu, M., Yoo, S., Zhong, J., and Amin, R.H., Published October 29th, 2020, “Drug discovery and development of novel therapeutics for inhibiting TMAO in models of atherosclerosis and diabetes.”, Frontiers in Physiology, Clinical and Translational Physiology
• Fu, X., Eggert, M., Patel, N., Yoo, S., Zhong, J., Steinke, I., Govindarajulu, M., Turumtay, E.A., Mouli, S., Panizzi, P., Beyers, R.J., Denney, T.S., Arnold, R.D., and Amin, R.H., Published April 12th, 2021, “The cardioprotective mechanism of Phenylaminoethyl Selenides (PAESe) against Doxorubicin-induced cardiotoxicity involves the iron sulfur protein frataxin.” Frontiers in Pharmacology